ERBB2 c.1183G>A ;(p.E395K)

Variant ID: 17-37871573-G-A

NM_004448.2(ERBB2):c.1183G>A;(p.E395K)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial.

Eclinicalmedicine
Goss, Glenwood D GD; Cobo, Manuel M; Lu, Shun S; Syrigos, Konstantinos K; Lee, Ki Hyeong KH; Göker, Erdem E; Georgoulias, Vassilis V; Isla, Dolores D; Morabito, Alessandro A; Min, Young J YJ; Ardizzoni, Andrea A; Bender, Shaun S; Cseh, Agnieszka A; Felip, Enriqueta E
Publication Date: 2021-07

Variant appearance in text: ERBB2: E395K
PubMed Link: 34195574
Variant Present in the following documents:
  • Main text
  • main.pdf
View BVdb publication page



Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care.

Oncotarget
Kong, Say Li SL; Liu, Xingliang X; Suhaimi, Nur-Afidah Mohamed NM; Koh, Kenneth Jia Hao KJH; Hu, Min M; Lee, Daniel Yoke San DYS; Cima, Igor I; Phyo, Wai Min WM; Lee, Esther Xing Wei EXW; Tai, Joyce A JA; Foong, Yu Miin YM; Vo, Jess Honganh JH; Koh, Poh Koon PK; Zhang, Tong T; Ying, Jackie Y JY; Lim, Bing B; Tan, Min-Han MH; Hillmer, Axel M AM
Publication Date: 2017-09-15

Variant appearance in text: ERBB2: E395K
PubMed Link: 28978093
Variant Present in the following documents:
  • oncotarget-08-68026-s002.xlsx, sheet 3
View BVdb publication page